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S UMM A R Y
IN T RODUC T ION : The World Health Organization rec-
ommends point-of-care (POC) lateral flow urine lip-
oarabinomannan (LF-LAM) for tuberculosis (TB)
diagnosis in selected human immunodeficiency virus
(HIV) positive people. South Africa had 438 000 new TB
episodes in 2016, 58.9% of which were contributed by
HIV-positive people. LF-LAM is being considered for
scale-up in South Africa.
METHODS : We estimated the costs of using LF-LAM in
HIV-positive adults with CD4 counts 6 150 cells/ll
enrolled in the TB Fast Track Trial in South Africa. We
also estimated costs of POC haemoglobin (Hb), as this
was used in the study algorithm. Data on clinic-level (10
intervention clinics) and above-clinic-level costs were
collected.
R E SU LT S : A total of 1307 LF-LAM tests were per-
formed at 10 clinics over 24 months. The mean clinic-
level costs were US$12.80 per patient for LF-LAM and
POC Hb; LF-LAM costs were US$11.49 per patient.
The mean above-clinic-level unit costs for LF-LAM were
US$12.06 for clinic preparation, training, coordination
and mentoring. The mean total cost of LF-LAM was
US$23.55 per patient.
CONC LU S I ON : At clinic level, the cost of LF-LAM was
comparable to other TB diagnostics in South Africa. It is
important to consider above-clinic-level costs for POC
tests, as these may be required to support roll-out and
ensure successful implementation.
K E Y WORD S : coinfection; diagnostic tests; point-of-
care systems; South Africa; tuberculosis
TUBERCULOSIS (TB) IS THE LEADING cause of
death in human immunodeficiency virus (HIV)
positive people. In 2016 alone, TB claimed the lives
of 1.67 million people worldwide, 0.37 million of
whom were HIV-positive.1 Difficulties in the diag-
nosis of TB among HIV-positive individuals have
brought about the need for new diagnostic methods;
lateral-flow urine lipoarabinomannan (LF-LAM)
antigen testing is one such method.2 Recent World
Health Organization (WHO) guidelines recommend
that countries use LF-LAM to assist in the diagnosis
of TB in HIV-positive adult in-patients and out-
patients who have signs and symptoms of TB and a
CD4 count 6 100 cells/ll.3 The WHO also
recommends LF-LAM for TB diagnosis in HIV-
positive adults who are seriously ill, regardless of
CD4 count.3
South Africa has one of the world’s highest TB
incidence rates, estimated at 781 per 100 000
population per year; 59% of individuals with
incident TB are HIV-positive.1 For countries such
as South Africa that are considering scaling up LF-
LAM, there is a need to evaluate costs, cost-
effectiveness and affordability, given their compet-
ing priorities and limited health sector budgets. A
previous study evaluating the costs and cost-effec-
tiveness of LF-LAM included only test costs.4 To
support investment decisions, however, all incre-
mental costs need to be considered in cost-effective-
ness analyses. A previous study on the costs of TB
diagnostics found that costs during roll-out may be
different from those observed at smaller scale.5
Measuring and analysing the full costs of imple-
menting TB diagnostics from pilot studies can assist
national programmes in making appropriate finan-
cial allocations to support the introduction of new
TB diagnostic tests.
The present study aimed to estimate costs of LF-
LAM used at point of care (POC) in primary health
clinics, including those incurred above the clinic level
and not directly at the clinics.6
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METHODS
Study setting
The cost estimation was conducted as part of the TB
Fast Track Trial, an open, pragmatic, two-arm,
cluster-randomised superiority trial with primary
health clinics (PHCs) as the unit of randomisation.7
The trial evaluated a novel algorithm, which included
LF-LAM, which was intended to enable nurses to
identify HIV-positive adults with low CD4 counts
who were at high risk of TB, and initiate rapid anti-
tuberculosis treatment (on the same day or within 1
week of enrolment), followed by prompt initiation of
antiretroviral therapy (ART). Clinics were rando-
mised to receive the intervention or standard of care
(ratio 1:1). At all clinics, participants who were HIV-
positive, with CD4 6 150 cells/ll, and who had not
received ARTor TB treatment in the preceding 6 or 3
months, respectively, were enrolled. The trial was
conducted between December 2012 and December
2014.
Intervention description
At enrolment, the research nurse in the intervention
clinics performed a POC LF-LAM test and a POC
haemoglobin (Hb) test (HemoCuew Hb 201þ, He-
moCue, Angelholm, Sweden) .7 The POCHb test was
conducted as part of the trial algorithm to assess TB
risk. Urine samples were tested using the Alere
Determinee TB LAM Ag assays (Alere Inc, Waltham,
MA, USA) according to the manufacturers’ guide-
lines. Stored LF-LAM test strips were removed from
the refrigerator to sit at room temperature for at least
1 h before use. A fresh urine sample was then
collected from the participant. Using a pipette, 60 ll
of the sample was introduced into the LF-LAM test
kit and left to incubate at room temperature for 25
min. A timer was set to ensure that the incubation
period was accurate and standardised for all samples.
At the end of the incubation period, the strips were
visually examined with the aid of a desk lamp: the
results were interpreted using the reference card
provided and recorded on individual worksheets. A
positive result required both the control and test band
to be visible; positive results were graded by matching
the intensity of the test band with bands on the
reference card, which ranged from 1þ to 5þ.
At the above-clinic level, a research team of six (one
project manager, one junior project manager and four
study coordinators) supported the clinics with study
activities. Their roles involved clinic preparation,
training, coordination, quality assurance and men-
toring. Clinic preparation included assessing clinics,
sourcing equipment, meetings, training clinic-based
staff and travel. Training activities included general
HIV-TB training, laboratory training for study tests
and follow-on training of clinic-based staff during the
pilot period. Coordination activities involved provi-
sion of required materials and equipment, and
organising and chairing team meetings to discuss
progress and provide supervision. Mentoring in-
volved supervising the nurses’ implementation of
the algorithm, as required, to ensure quality test
results.
Scope of costing
We investigated, from a health care system perspec-
tive, the full economic costs of LF-LAM as an initial
TB diagnostic test in HIV-positive individuals with
CD4 count6 150 cells/ll in South African PHCs. We
also estimated the costs of POC Hb testing conducted
as part of the trial, as this was also used in the trial
algorithm. We used a micro-costing approach where
the resources used and their prices were enumerated.8
We costed two time periods: start-up and implemen-
tation. We estimated the unit cost per LF-LAM test
conducted and the unit cost per POC Hb test
conducted.
Clinic selection
The clinics selected to participate in the trial had the
capacity to initiate and deliver TB treatment and ART
and had sufficient numbers of patients initiating ART
with low CD4 counts.5 Clinics with on-site labora-
tories capable of performing smear microscopy and
Xpertw MTB/RIF (Cepheid, Sunnyvale, CA, USA)
with same-day results were excluded.7 Clinics were
also chosen to ensure a combination of both peri-
urban and rural PHCs. The sampling frame for this
economics study was the 12 intervention clinics in the
trial; however, due to practical constraints, costs were
collected from 10 clinics. These clinics were in four
districts: the Tshwane and Ekurhuleni Districts in
Gauteng, the Greater Tubatse District in Limpopo,
and the Bojanala District in the Northwest.
Costing methods
We collected cost data at clinic level and above clinic
level from June 2012 to April 2014. At clinic level, all
resources were collected using a bottom-up costing
approach, where detailed activity and input usage
data were found in records (or observations) at the
service provider level to estimate unit costs.5 Re-
source use at clinic level was measured using direct
observation to ensure that all resource uses were
included; any time spent on research activities, such
as completing case report forms, was excluded.
Resources included were staff salaries, equipment
and supplies. To estimate human resource use, the
nurses who carried out the investigations were
observed performing the diagnostic procedures
(POC LF-LAM and POC Hb) 4–8 times at each of
the 10 clinics. The resources used and time spent per
activity were recorded.
At above clinic level, a top-down approach was
used for resource use measurement, where overall
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expenditures for each input were allocated using an
activity-based approach to estimate unit costs.5
Recorded activities were grouped into two categories:
clinic preparation and training for start-up, and
coordination and mentoring during implementation.
Human resource time was measured using prospec-
tively completed timesheets, followed by staff inter-
views for clarification. Research activities were
excluded. Financial records from the trial were
reviewed to measure other resource use, such as staff
transportation and training costs. Results were
discussed with project management staff to ensure
all research time had been correctly excluded. As
coordination and mentoring activities were mostly
research-related, only 1% of this cost was included,
with the rest allocated to research. We then allocated
60% of the implementation cost to LF-LAM, based
on staff reporting of how their time was spent.
For all the abovementioned clinic-level staff costs,
two approaches were used to estimate salaries, as
staff employed on research projects may cost more
than government staff, who are expected to support
any LF-LAM introduction in practice. First, payroll
costs were converted into a wage per minute by
assuming staff worked 8 h a day. Second, National
Department of Health (NDoH) salaries were applied
to district and provincial coordinators. All other
above-clinic-level prices were obtained from project
financial records. For supplies, the unit price of the
standard package of supplies used at each clinic for
LF-LAM and POC Hb testing was sourced from
project invoices. Building costs per square metre for a
typical public clinic were obtained from NDoH.
We classified any costs that were incurred before
LF-LAM was conducted at clinics as start-up costs,
and annuitised these over their various useful lives
using a discount rate of 3%. The start-up costs were
related to capital inputs such as training, buildings,
furniture and equipment. A useful life of 2 years was
used for training, based on staff turnover, 5 years for
furniture and equipment, and 20 years for buildings.
All costs are presented in 2014 United States dollars
($US). South African rands (ZAR) were converted
into $US using an exchange rate of ZAR10.71 to
US$1. Microsoft Excel (MicroSoft, Redmond, WA,
USA) was used for all analyses.
Ethics
The parent trial received approval from the Research
Ethics Committees of the University of Witwaters-
rand, Johannesburg, South Africa (ref: R14/49
M111177); the London School of Hygiene &
Tropical Medicine, London, UK (ref: 6099); and
the Provincial Research Committees of Gauteng,
North West, and Limpopo Provinces, Pretoria,
South Africa. The trial was registered with the South
African Medicines Control Council (Pretoria, South
Africa) as a Phase IV clinical trial (ref N2/19/8/2
#20120157), with the Current Controlled Trials (ref:
ISRCTN35344604 (23)), and the South African
Registry (ref: DOH-27-0812-3902). All participants
provided written informed consent for inclusion in
the parent trial; no individual consent was sought for
the costing study, as all persons interviewed were
those employed by the project.
RESULTS
Seven peri-urban and three rural clinics were included
(Table 1). The mean number of ART initiations per
month ranged from 16 to 66 in the 3 months before
enrolment. The mean number of LF-LAM tests
ranged from 3.71 to 6.63 per month. A total of
1307 LF-LAM tests were performed over the 24
months from December 2012 to December 2014.
The mean clinic-level unit costs were US$12.80 per
patient for LF-LAM and POC Hb procedures
combined (using non-governmental organisation
Table 1 Description of the 10 intervention clinics
Clinic District Province Location
Mean ART
initiations/month
n*
Mean LF-LAM
tests/month
n†
Total LF-LAM tests
performed over
24 months
n†
1 Tshwane Gauteng Peri-urban 33 6.25 150
2 Tshwane Gauteng Peri-urban 30 5.96 143
3 Tshwane Gauteng Peri-urban 33 3.63 87
4 Tshwane Gauteng Peri-urban 39 5.83 140
5 Tshwane Gauteng Peri-urban 20 4.54 109
6 Tshwane Gauteng Peri-urban 70 6.63 159
7 Tshwane Gauteng Peri-urban 35 5.83 140
8 Bojanala Northwest Rural 16 3.71 89
9 Greater Tubatse Limpopo Rural 44 5.83 140
10 Ekurhuleni Gauteng Rural 66 6.25 150
Total 386 54.46 1,307
Mean 39 5.446 13.07
*ART initiations before the trial period.
† POC LF-LAM tests performed as part of the trial.
ART¼antiretroviral therapy; LF-LAM¼ lateral flow urine lipoarabinomannan.
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[NGO] salaries); the mean clinic-level costs of LF-
LAM and POC Hb were respectively US$11.50 and
US$1.31 (Table 2). For both procedures combined,
staff costs (US$8.01) and supplies (US$3.30) were the
two largest input costs at clinic level. Staff costs for
LF-LAM using research nurse salary scales amounted
to US$7.50 per patient, whereas with the NDoH
scales they were less than a dollar cheaper, at US$6.86
per patient. Equipment and furniture were the least
costly, at US$0.01 per patient.
The cost of LF-LAM varied by clinic from US$9.96
to US$13.06 (Table 3), with most of the variation
being driven by staff costs. Table 4 presents the total
costs incurred above the clinic level over a 24-month
period. Building costs here are not annuitized, as they
were derived from a monthly cost. The total cost
(using NGO salaries) incurred across all 10 clinics
was US$15 763. Over half of this cost was incurred
during start-up. Most of the funding was spent on
training, with the most significant cost driver here
being staff salaries. For clinic preparation and
mentoring, staff costs were the key cost driver. For
coordination, however, equipment and furniture were
the main cost drivers; these included laptops,
telephones, desks and chairs used above clinic level.
The above-clinic-level unit costs for LF-LAM were
US$12.06 for clinic preparation, training, coordina-
tion and mentoring (Table 5). When both above-
clinic-level and clinic-level unit costs for LF-LAM
were combined, the total cost of LF-LAM per patient
was US$23.55 (US$11.49 clinic-level and US$12.06
above-clinic-level). When using NDoH salaries, the
total unit cost of LF-LAM was comparable, at
US$22.72 per patient (US$10.85 clinic-level and
US$11.87 above-clinic-level).
DISCUSSION
The total unit costs of LF-LAM testing at US$23.55
were considerably higher than previous estimates due
to the use of a micro-costing approach and the
inclusion of the above-clinic-level costs required to
support POC implementation. At both clinic level
and above clinic levels, staff costs were the primary
Table 2 Mean clinic-level unit costs for LF-LAM and POC Hb testing by test and input (2014 $US)
Input
Cost in 2014 $US
LF-LAM
mean* (range)
POC Hb
mean* (range)
Total
mean*
Capital costs
Building 0.535 (0.208–1.305) 0.041 (0.007–0.129) 0.670
Equipment and furniture 0.009 (,0.001–0.030) 0.005 (,0.001–0.006) 0.014
Total 0.638 (0.208–1.336) 0.046 (0.007–0.135) 0.684
Recurrent costs
Staff salaries (NGO) 7.501 (6.008–9.585) 0.512 (0.212–0.746) 8.013
Staff salaries (NDoH)† 6.863 (5.729–8.416)† 0.479 (0.203–0.711)† 7.341†
Supplies 2.592 (2.591–2.593) 0.711 (0.710–0.712) 3.303
Utilities 0.716 (0.342–1.380) 0.039 (0.013–0.112) 0.801
Total (NGO) 10.854 (8.941–13.557) 1.262 (0.936–1.570) 12.116
Total (NDoH) 10.216 (8.662–12.389) 1.229 (0.926–1.536) 11.445
Total costs (NGO) 11.492 (9.149–14.893) 1.308 (0.943–1.706) 12.800
Total costs (NDoH)† 10.854 (9.149–13.724)† 1.275 (0.933–1.672)† 12.129†
*Mean (weighted by volume) across all sites.
† NDoH staff salaries applied.
LF-LAM¼ lateral flow urine lipoarabinomannan; POC¼point-of-care; Hb¼haemoglobin; $US¼United States dollars;
NDoH¼National Department of Health; NGO¼ non-governmental organisation.
Table 3 Mean unit costs for lateral flow urine lipoarabinomannan testing by clinic (2014 $US)
Clinic
number
Unit cost
(NGO)
$US
Unit cost
(NDoH)
$US
Staff salaries
(NGO)
$US
Staff salaries
(NDoH)
$US
Building
$US
Equipment
and furniture
$US
Utilities
$US
Supplies
$US
1 12.500 12.163 7.267 6.929 1.259 0.006 1.380 2.590
2 10.418 10.087 7.127 6.795 0.272 0.007 0.422 2.591
3 9.965 9.660 6.567 6.262 0.227 0.007 0.572 2.592
4 10.518 10.213 6.578 6.272 0.365 0.007 0.977 2.593
5 12.802 11.349 8.410 6.956 0.472 0.007 1.320 2.593
6 11.207 10.247 7.878 6.918 0.327 0.007 0.404 2.591
7 13.062 11.956 9.076 7.970 0.492 0.009 0.894 2.591
8 12.226 11.434 7.568 6.791 1.110 0.007 0.949 2.592
9 10.345 10.508 6.936 7.100 0.438 0.023 0.357 2.591
10 10.935 9.966 7.603 6.635 0.386 0.011 0.342 2.592
Mean* 11.398 10.760 7.501 6.863 0.535 0.009 0.762 2.592
*Unweighted mean across all sites.
$US¼ United States dollars; NDoH¼ National Department of Health; NGO¼ non-governmental organisation.
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cost driver. A previous study considered only the cost
of the LF-LAM test kit (US$3.50), thus underesti-
mating clinic-level and above-clinic-level costs by
90%.3
The above-clinic-level costs of using LF-LAM were
higher than we found for other TB diagnostic tests
implemented in South Africa. For example, in a
previous study, the above-clinic-level cost of Xpert
was found to be US$5.80 per test.5 However, as the
Xpert study was implemented at the laboratory level
and during large-scale roll-out, it benefited from
economies of scale. It is also likely that our above-
clinic-level costs would fall over time. Nevertheless, it
is conceivable that for LF-LAM the ratio of tests to
nurses may increase as staff become more proficient
at organising and carrying out the tests, leading to a
reduction in costs. In addition, if a newer, more
sensitive LF-LAM test became available, which could
be used more widely, further economies of scale
would be realised.
If the LF-LAM test were to be rolled out nationally,
some of the activities may also be conducted
differently. For example, clinic preparation could be
done centrally and would not require multiple site
visits. A single trip to conduct regional training for
multiple sites on the use of LF-LAMmay also suffice.
Staff travel costed here was estimated from the head
office, 400 km away from the furthest clinic. It is
unlikely that support travel costs would need to be
based outside the local region for national roll-out.
Table 4 Total costs of lateral flow urine lipoarabinomannan testing at above clinic level by input over a 24-month period, 2014 $US
Input
Start-up (6 months) Implementation (16 months) Total
Total cost of
clinic preparation
%/column total
Total cost of
training*
%/column total
Total cost of
coordination
%/column total
Total cost of
mentoring
%/column total
Total cost (NGO)
%/column total
Total cost (NDoH)
%/column total
Capital costs
Building 100 (11.8) 100 (0.6) 100 (0.6)†
Equipment and furniture 571 (67.6) 571 (3.6) 571 (3.7)†
Training‡ 3 270 (34.7) 3 270 (20.7) 3 270 (21.1)†
Total 3 270 (34.7) 671 (79.3) 3 941 (25.0) 3 941 (25.4)†
Recurrent costs
Staff salaries (NGO)§ 3 249 (64.5) 5 412 (57.4) 140 (16.5) 412 (90.5) 9 212 (58.4)
Staff salaries (NDoH)† 3 492 (66.1)† 4 870 (54.8)† 159 (18.4)† 439 (91.1)† 8 960 (57.8)†
Travel 1 312 (26.0) 714 (7.6) 36 (7.5) 2 062 (13.1) 2 062 (13.3)†
Administration 408 (8.1) 28 (3.3) 435 (2.8) 435 (2.8)†
Utilities 71 (1.4) 28 (0.2) 7 (0.8) 7 (1.5) 113 (0.7) 113 (0.7)†
Total 5 039 (100) 6 154 (65.3) 175 (20.6) 455 (100) 11 822 (75.0) 11 570 (74.6)†
Total costs 5 039 (100) 9 425 (100) 846 (100) 455 (100) 15 763 (100) 15511 (100)
* Training on HIV-TB was conducted by the above-clinic-level staff.
† NDoH staff salaries applied.
‡ Training was conducted by the laboratory staff on how to conduct the tests (not possible to break down by input, included trainer, materials, staff transport to
venue, furniture and training room).
§ Staff salaries from NGO not always higher than NDOH and, in some cadres, these are lower.
$US ¼ United States dollars; NDoH ¼ National Department of Health; NGO ¼ non-governmental organisation; HIV ¼ human immunodeficiency virus; TB ¼
tuberculosis.
Table 5 Total LF-LAM unit costs at above clinic and clinic levels by input (2014 $US)
Input (n ¼ 1307)
Total unit cost of LF-LAM ($US)
Start-up Implementation Totals
Clinic
preparation Training Coordination Mentoring Above-clinic Clinic
Total above-clinic
and clinic levels
NGO NDoH NGO NDoH NGO NDoH NGO NDoH NGO NDoH NGO NDoH NGO NDoH
Capital costs
Building 0.08 0.08 0.08 0.08 0.63 0.63 0.71 0.71
Equipment and furniture 0.44 0.44 0.44 0.44 0.01 0.01 0.45 0.45
Training 2.50 2.50 2.50 2.50 2.50 2.50
Total 2.50 2.50 0.51 0.51 3.02 3.02 0.64 0.64 3.66 3.66
Recurrent costs
Staff salaries 2.49 4.68 4.14 3.73 0.11 0.12 0.31 0.34 7.05 6.86 7.50 6.86 14.55 13.72
Travel 1.00 1.00 0.55 0.55 0.03 0.03 1.58 1.58 1.58
Administration 0.31 0.31 0.02 0.02 0.33 0.33 0.33
Utilities 0.05 0.05 0.02 0.02 0.01 0.01 0.01 0.01 0.09 0.09 0.72 0.72 0.81 0.81
Supplies 2.59 2.59 2.59 2.59
Total 3.86 6.05 4.71 4.29 0.14 0.15 0.35 0.37 9.05 8.85 10.85 10.22 19.90 19.07
Total 3.86 6.05 7.21 6.80 0.65 0.66 0.35 0.37 12.06 11.87 11.49 10.85 23.55 22.72
LF-LAM¼ lateral flow urine lipoarabinomannan; $US¼ United States dollars; NDoH¼ National Department of Health; NGO¼ non-governmental organisation.
1086 The International Journal of Tuberculosis and Lung Disease
Furthermore, the scale-up of LF-LAM would not
require POC Hb. However, national roll-out may
incur additional costs to be able to manage the
complexity of a technology adoption process at scale.
If LF-LAM were implemented only in patients with
CD4 count 6 100 cells/ll, then economies of scale
would be reduced. It is therefore recommended that
LF-LAM be re-costed post roll-out for long-term
budget planning.
The study had limitations. First, it should be noted
that South Africa has higher staff salaries than other
settings, so care should be taken when generalising
these costs in settings with lower salaries and higher
test volumes. Second, our sampling strategy was
driven by the trial’s clinic selection; without these
restrictions, we might have included better-perform-
ing clinics that may have been more efficient (and
less costly to support) or, conversely, worse-per-
forming clinics that might have been more costly to
support. Third, in the same light, we may have
missed some of the health systems investments that
may be necessary for weaker clinics; our methods for
bottom-up costing, primarily using observation,
may also have biased costs downwards, due to the
observer, or ‘Hawthorne’, effect. Fourth, the above-
clinic-level staff could not be observed performing
their duties and we had to rely on their self-
completed timesheets; this may have resulted in
errors in estimating how much time was spent on
specific activities.
CONCLUSIONS
Our study highlights the importance of conducting
comprehensive micro-costing of new TB tests before
the decision is taken to roll them out. Accurate,
unbiased cost data are essential to inform economic
evaluations and financial decisions. For successful
implementation, care should be taken to ensure that
roll-out is adequately funded, including all the
support costs that POC tests often require.
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R E´ S U M E´
I N T RODUC T ION : L’Organisation Mondiale de la Sante´
recommande un diagnostic de la tuberculose (TB) sur
place (POC) par dosage de lipoarabinomannane par flux
late´ral sur l’urine (LF-LAM) chez des personnes
se´lectionne´es positives pour le virus de
l’immunode´ficience humaine (VIH). L’Afrique du Sud
a eu 438 000 nouveaux e´pisodes de TB en 2016, dont
58,9% e´taient des personnes positives au VIH. L’Afrique
du Sud envisage une expansion du LF-LAM.
M E´ T H O D E : Nous avons estime´ les couˆts de
l’utilisation du LF-LAM chez les adultes VIH positifs
avec des comptages CD46 150 cellules/ll enroˆle´s dans
l’essai TB Fast Track en Afrique du Sud. Nous avons
e´galement estime´ les couˆts du dosage sur place de
l’he´moglobine (Hb), car celui-ci a e´te´ utilise´ dans
l’algorithme de l’e´tude. Des donne´es relatives aux
couˆts au niveau des structures de sante´ (10 centres
d’intervention) et au-dela` des structures de sante´ ont e´te´
recueillies.
R E´ S U LTAT S : Un total de 1307 tests LF-LAM a e´te´
re´alise´ dans 10 centres en 24 mois. Les couˆts moyens
pour les centres ont e´te´ de US$12,80 par patient pour le
LF-LAM et l’Hb sur place ; le couˆt du LF-LAM a e´te´ de
US$11,49 par patient. Les couˆts unitaires moyens au-
dela` des structures de sante´ du LF-LAM ont e´te´ de
US$12,06 pour la pre´paration, la formation, la
coordination et le tutorat. Le couˆt total moyen du LF-
LAM a e´te´ de US$23,55 par patient.
CONC LU S I ON : Au niveau des centres, le couˆt du LF-
LAM a e´te´ comparable aux autres diagnostics de TB en
Afrique du Sud. Il est important de tenir compte des
couˆts au-dela` des structures de sante´ des tests sur place,
car ils peuvent eˆtre ne´cessaires pour soutenir le
lancement et assurer une mise en œuvre fructueuse.
R E S UM E N
MARCO DE R E F E R ENC I A: La Organizacio´n Mundial de
la Salud recomienda que se utilice la prueba de flujo
lateral de lipoarabinomanano en orina (LF-LAM) en el
lugar de la consulta (POC) para el diagno´stico de la
tuberculosis (TB) en determinadas personas positivas
frente al virus de la inmunodeficiencia humana (VIH).
En Sura´frica ocurrieron 438 000 nuevos episodios de TB
en el 2016, de los cuales el 58,9% afecto´ a personas
positivas frente al VIH; en la actualidad se considera la
posibilidad de ampliar la escala de aplicacio´n de la
prueba de LF-LAM en el paı´s.
M E´ TODOS: Se estimaron los costos de la utilizacio´n de
la prueba LF-LAM en los adultos positivos frente al
VIH con una cifra de linfocitos CD4 6 150 ce´lulas/ll
que participaron en el estudio ‘TB Fast Track’ en
Sura´frica. Se estimaron adema´s los costos de
determinacio´n de la hemoglobina (Hb) en el POC,
pues esta prueba formaba parte del algoritmo del
estudio. Se recogieron datos sobre los costos a escala de
los consultorios (10 consultorios que participaron en la
intervencio´n) y los costos a un nivel superior del
consultorio.
R E SU LTADOS: Se realizaron 1307 pruebas de LF-LAM
en 10 consultorios durante 24 meses. El promedio de los
costos en los consultorios fue US$12,80 por paciente
para la LF-LAM y la Hb en el POC; la prueba LF-LAM
costo´ US$11,49 por paciente. El promedio de los costos
unitarios de la prueba FL-LAM en el nivel superior al
consultorio fue US$12,06, destinados a la preparacio´n,
la capacitacio´n, la coordinacio´n y la tutorı´a en los
consultorios. El promedio del costo total de la prueba
LF-LAM fue US$23,55 por paciente.
CONC LU S I O´ N: A escala del consultorio, el costo de la
prueba LF-LAM fue equivalente al costo de otros medios
diagno´sticos que se utilizan en Sura´frica. Es importante
tener en cuenta los costos de las pruebas aplicables en el
POC a un nivel superior del consultorio, pues
corresponden a actividades que pueden ser necesarias
para respaldar el despliegue de las pruebas y garantizar
su utilizacio´n eficaz.
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